Artemisinin Antimalarial Drugs Market Analysis

Artemisinin Antimalarial Drugs Market Analysis

To get key market trends

  Download Free Sample

Based on the malaria type, the artemisinin antimalarial drugs industry is categorized into Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, and Plasmodium knowlesi. The Plasmodium falciparum segment dominated the market with USD 553.8 million in 2023.
 

• Plasmodium falciparum, the most virulent of the malaria-causing parasites, holds a significant market share in the industry due to its high prevalence and the severity of the infections it causes.
   
• Artemisinin-based combination therapies (ACTs) are the frontline treatment for P. falciparum malaria, given their effectiveness in rapidly clearing the parasite from the bloodstream and reducing mortality.
   
• The high burden of P. falciparum malaria, particularly in regions of Sub-Saharan Africa and Southeast Asia, drives the demand for these treatments.
   
• Consequently, the market for artemisinin antimalarial drugs is heavily influenced by the need to combat P. falciparum, reinforcing its dominant position within the therapeutic landscape.
   

Based on product, the artemisinin antimalarial drugs market is segmented into antimalarial injections and antimalarial tablets. The antimalarial tablets segment is dominated the market holding the highest market share of 80.5% in 2023.
 

• High market share of artemisinin antimalarial tablets can be attributed to their widespread use and effectiveness in treating malaria.
   
• These tablets, often formulated with artemisinin derivatives such as artemether and lumefantrine, are preferred for their potent antimalarial properties and convenience of administration.
   
• Additionally, the integration of antimalarial tablets into national treatment guidelines and their availability in both public health systems and private markets contribute to their dominant position in the market.
   

Based on the type, the artemisinin antimalarial drugs market is segmented into monotherapy and combination therapy. The combination therapy segment is projected to reach USD 660.7 million by 2032.
 

• Combination therapy holds a significant market share in the artemisinin antimalarial drugs industry due to its enhanced efficacy in treating and preventing malaria. This therapeutic approach, which combines artemisinin-based compounds with other antimalarial agents, helps to address drug resistance issues and improve treatment outcomes.
   
• By leveraging the synergistic effects of multiple drugs, combination therapy not only increases the overall efficacy of malaria treatment but also reduces the likelihood of resistance developing.
   
• This strategy aligns with global health guidelines and is supported by extensive clinical evidence, contributing to its dominant position in the market.
   

Middle East & Africa market was valued at USD 231.5 million in 2023 and is expected to witness growth at a CAGR of 4.1% between 2024 – 2032.
 

• The Middle East and Africa (MEA) region holds a significant market share in the artemisinin antimalarial drugs market due to the high prevalence of malaria in several countries within the region.
   
• The ongoing efforts to combat malaria through various health initiatives and the strong support from both governmental and non-governmental organizations contribute to the robust market presence.
   
• Additionally, the increasing investments in healthcare infrastructure, rising awareness about malaria prevention, and the growing availability of artemisinin-based combination therapies (ACTs) have bolstered the region’s market share.
   
• These factors, combined with the region's strategic focus on improving treatment outcomes and access to antimalarial drugs, underscore its crucial role in the global market.
   

Asia Pacific region accounted for the second largest share of 26.7% in 2023. 
 

• Countries such as India, Pakistan, Indonesia, and others suffer from a high burden of malaria cases in the region. India is known for the world's third-highest malaria burden. 
   
• Similarly, as per the World Malaria Report, in 2022, India accounted for 66% of malaria cases in the WHO South-East Asia region.
   
• Additionally, several initiatives taken by public organizations in the APAC countries to reduce the burden of malaria and provide proper treatment are expected to boost the market in Asia Pacific. 
   
• For instance, the government of India developed a National Strategic Plan (NSP, 2017-2022) and National Framework for Malaria Elimination (2016-2030) to eradicate malaria disease by providing treatment at a low cost. 
   
• Such initiatives are likely to support the market in Asia Pacific in the forecast.
   

Latin American region presents significant growth potential in the artemisinin antimalarial drugs market due to a combination of factors. 
 

• The increasing incidence of malaria in certain areas, coupled with the growing awareness and implementation of malaria control programs, is driving demand for effective antimalarial treatments. 
   
• Moreover, the region's improving healthcare infrastructure and increased investment in pharmaceutical research and development are contributing to the expansion of market opportunities. 
   
• Additionally, the rising focus on improving access to essential medicines in underserved areas supports the demand for artemisinin-based therapies, positioning Latin America as a promising market for growth in the coming years.